期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 233, 期 1, 页码 153-161出版社
WILEY
DOI: 10.1002/jcp.25804
关键词
cardiovascular disease; diabetes; lipids; metabolism; peroxisome proliferator-activated receptors; therapy
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in several physiological processes including modulation of cellular differentiation, development, metabolism of carbohydrates, lipids, proteins, and tumorigenesis. The aim of this review is to examine how different PPAR ligands act, and discuss their use in clinical practice. PPAR ligands have a lot of effects and applications in clinical practice. Some PPAR ligands such as fibrates (PPAR-alpha ligands) are currently used for the treatment of dyslipidemia, while pioglitazone and rosiglitazone (PPAR-gamma ligands) are anti-diabetic and insulin-sensitizing agents. Regarding new generation drugs, acting on both alpha/gamma, beta/delta, or alpha/delta receptors simultaneously, preliminary data on PPAR-alpha/gamma dual agonists revealed a positive effect on lipid profile, blood pressure, atherosclerosis, inflammation, and anti-coagulant effects, while the overexpression of PPAR-beta/delta seems to prevent obesity and to decrease lipid storage in cardiac cells. Finally, PPAR-alpha/delta dual agonist induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据